Multiple Myeloma

Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors

Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors

Seeking Alpha

Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting

Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting

Yahoo/MarketWire

Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug

Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug

Bloomberg

Celgene's Star Drug Revlimid And Its Competitors

Celgene's Star Drug Revlimid And Its Competitors

Seeking Alpha

Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover

Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover

Bloomberg

Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation

Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation

Yahoo

Celgene And The Race To Cure Multiple Myeloma

Celgene And The Race To Cure Multiple Myeloma

Seeking Alpha

Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?

Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?

Motley Fool

Celgene Gets OK to Sell Blood Cancer Drug

Celgene Gets OK to Sell Blood Cancer Drug

Minyanville

Still Revving Up With Revlimid

Still Revving Up With Revlimid

Motley Fool